Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.36 |
| ▸ | TACR1 | P25103 | 3/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17140968 | 0.91 | ME2 (0.33) | ENPP2 | |
| SCHEMBL18940792 | 0.90 | CYP2C9 (0.36) | CYP2C19CYP1A2 | |
| SCHEMBL17140987 | 0.89 | ALDH1A1 (0.41) | ALDH1A1USP2MAPK1CYP2C19 | |
| SCHEMBL17140959 | 0.89 | ITGB3 (0.35) | ENPP2 | |
| SCHEMBL17141087 | 0.88 | ITGAL (0.36) | ENPP2ALDH1A1USP2MAPK1CYP2C19 | |
| SCHEMBL17140628 | 0.87 | ALDH1A1 (0.35) | ENPP2ALDH1A1 | |
| SCHEMBL17140871 | 0.87 | MAPT (0.37) | ALDH1A1MAPK1 | |
| SCHEMBL17140941 | 0.86 | ENPP2 (0.40) | ENPP2 | |
| SCHEMBL18940800 | 0.86 | MAPT (0.38) | ENPP2ALDH1A1USP2 | |
| SCHEMBL18940712 | 0.84 | ENPP2 (0.30) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10233182-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180282332-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. | 2018-10-04 | — | — | US | disclosed |
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170166568-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| EP-3125895-A1 | SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN | X-RX, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015154023-A1 | SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN | X-RX DISCOVERY, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166568-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, SLC10A1, CXCR3 | ENPP2 1/4885ALDH1A1 1493/4885ATM 3673/4885 |
| US-10233182-B2 | Substituted spirocyclic inhibitors of autotaxin | ENPP2, CXCR3, SLC10A1 | ENPP2 1/4885ALDH1A1 1900/4885ATM 3604/4885 |
| US-20180282332-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, CXCR3, SLC10A1 | ENPP2 1/4885ALDH1A1 1900/4885ATM 3604/4885 |
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, SLC10A1, CXCR3 | ENPP2 1/4885ALDH1A1 1493/4885ATM 3673/4885 |
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | ENPP2, SLC10A1, CXCR3 | ENPP2 1/4885ALDH1A1 1493/4885ATM 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.